TEAD3

Chr 6

TEA domain transcription factor 3

Also known as: DTEF-1, ETFR-1, TEAD-3, TEAD5, TEF-5, TEF5

NCBI Gene: 7005ENSG00000007866UniProt: Q99594

This gene product is a member of the transcriptional enhancer factor (TEF) family of transcription factors, which contain the TEA/ATTS DNA-binding domain. It is predominantly expressed in the placenta and is involved in the transactivation of the chorionic somatomammotropin-B gene enhancer. Translation of this protein is initiated at a non-AUG (AUA) start codon. [provided by RefSeq, Jul 2008]

52
ClinVar variants
7
Pathogenic / LP
0.99
pLI score· haploinsufficient
0
Active trials
Clinical Summary— TEAD3
⚡
Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 0.99). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
7 Pathogenic / Likely Pathogenic· 45 VUS of 52 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

gnomAD
LoF intolerant — likely haploinsufficient
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.26LOEUF
pLI 0.994
Z-score 4.15
OE 0.08 (0.03–0.26)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
2.76Z-score
OE missense 0.53 (0.46–0.60)
141 obs / 268.3 exp
Mild constraint

Moderately missense-constrained (top ~2.5%)

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.08 (0.03–0.26)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.53 (0.46–0.60)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.77
0≤1.21.6
LoF obs/exp: 2 / 23.9Missense obs/exp: 141 / 268.3Syn Z: 1.93

ClinVar Variant Classifications

52 submitted variants in ClinVar

ClinVar

Classification Summary

Pathogenic5
Likely Pathogenic2
VUS45
5
Pathogenic
2
Likely Pathogenic
45
VUS

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
5
0
5
Likely Pathogenic
0
1
1
0
2
VUS
0
43
2
0
45
Likely Benign
0
0
0
0
0
Benign
0
0
0
0
0
Total0448052

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

TEAD3 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

OMIM
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
Long noncoding RNA Malat1 protects against osteoporosis and bone metastasis.
Zhao Y et al.·Nat Commun
2024
TEAD3 inhibits the proliferation and metastasis of prostate cancer via suppressing ADRBK2.
Wang C et al.·Biochem Biophys Res Commun
2023
Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors.
Kovács SA et al.·Acta Pharmacol Sin
2023
Hippo pathway effectors are associated with glioma patient survival, control cell proliferation and sterol metabolism through TEAD3.
Masliantsev K et al.·Brain Pathol
2025
TEAD3 + high-risk melanoma cells crosstalk with GAS6 + macrophages via the GAS6-TYRO3 ligand-receptor axis to modulate propionate metabolism and drive melanoma progression.
Fang Y et al.·J Exp Clin Cancer Res
2025
Modeling SMAD2 Mutations in Induced Pluripotent Stem Cells Provides Insights Into Cardiovascular Disease Pathogenesis.
Ward T et al.·J Am Heart Assoc
2025Functional
YAP/TEAD3 signal mediates cardiac lineage commitment of human-induced pluripotent stem cells.
Han Z et al.·J Cell Physiol
2020
Chemically defined and growth factor-free system for highly efficient endoderm induction of human pluripotent stem cells.
Zhao Z et al.·Stem Cell Reports
2025
Identification of heterogeneity and common characteristics in colorectal carcinoma located in distinct sites.
Luo Y et al.·Sci Rep
2025
EphA2 promotes the transcription of KLF4 to facilitate stemness in oral squamous cell carcinoma.
Bai J et al.·Cell Mol Life Sci
2024
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC
Top 5 resultsSearch Europe PMC ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →

External Resources

Links to major genomics databases and tools